Go to content
UR Home

Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA)

Hayden, P.J. ; Roddie, C. ; Bader, P. ; Basak, G.W. ; Bonig, H. ; Bonini, C. ; Chabannon, C. ; Ciceri, F. ; Corbacioglu, S. ; Ellard, R. ; Sanchez-Guijo, F. ; Jäger, U. ; Hildebrandt, M. ; Hudecek, M. ; Kersten, M.J. ; Köhl, U. ; Kuball, J. ; Mielke, S. ; Mohty, M. ; Murray, J. ; Nagler, A. ; Rees, J. ; Rioufol, C. ; Saccardi, R. ; Snowden, J.A. ; Styczynski, J. ; Subklewe, M. ; Thieblemont, C. ; Topp, M. ; Ispizua, Á.U. ; Chen, D. ; Vrhovac, R. ; Gribben, J.G. ; Kröger, N. ; Einsele, H. ; Yakoub-Agha, I.


Background: Several commercial and academic autologous chimeric antigen receptor T-cell (CAR-T) products targeting CD19 have been approved in Europe for relapsed/refractory B-cell acute lymphoblastic leukemia, high-grade B-cell lymphoma and mantle cell lymphoma. Products for other diseases such as multiple myeloma and follicular lymphoma are likely to be approved by the European Medicines Agency ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons